Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A targeted antibody shows sustained results in a tough-to-treat skin disease. The AMETHYST trial found that litifilimab (Biogen) continued to improve skin clearance in cutaneous lupus patients through 52 weeks, with roughly a third achieving clear or near-clear skin. Patients who switched from placebo to the drug in the second half of the trial saw dramatic gains, underscoring the drug's real-world potential.
Litifilimab, a monoclonal antibody developed by Biogen, kept delivering skin improvements in patients with cutaneous lupus erythematosus (CLE) all the way through 52 weeks in the phase 2/3 AMETHYST trial — the first CLE study designed with this kind of long-term follow-up. The drug works by binding to a receptor on plasmacytoid dendritic cells, blocking the release of inflammatory signals like type I interferon that drive the disease.
Among patients who stayed on litifilimab throughout the trial, about 27% achieved clear or near-clear skin by week 52 — up from 19% at week 24. Even more striking: patients who started on placebo and switched to the drug in the second half of the trial saw their clear-skin rates jump from just 4.2% to 33.7%. Patient-reported outcomes told a similar story, with over 72% of switchers reporting their skin was "much better or moderately better" by week 52.
By the Numbers:
Why it matters: Cutaneous lupus can cause severe scarring, discoloration, and disfigurement, yet treatment options remain limited. These 52-week results suggest litifilimab could offer durable, meaningful skin clearance — a significant step forward for patients with this chronic and often debilitating condition.
